Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
暂无分享,去创建一个
H. Lan | K. Jin | Bo Wu | Yefeng Chen
[1] Xu Zhang,et al. The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review , 2023, Frontiers in oncology.
[2] Wei Guo,et al. Chromatin accessibility dynamics in colorectal cancer liver metastasis: uncovering the liver tropism at single cell resolution. , 2023, Pharmacological research.
[3] Hailin Tang,et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer , 2023, Molecular Cancer.
[4] Shota Katayama,et al. Targeting c-Jun is a potential therapy for luminal breast cancer bone metastasis. , 2023, Molecular cancer research : MCR.
[5] Zhifu Yang,et al. Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression. , 2023, Acta biomaterialia.
[6] T. Nishimura,et al. Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312). , 2023, Lung cancer.
[7] Bixiang Zhang,et al. Bone Lesion‐Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5‐Targeting miR‐3190‐5p , 2023, Advanced science.
[8] Wenhao Zhou,et al. Targeting nano-regulator based on metal–organic frameworks for enhanced immunotherapy of bone metastatic prostate cancer , 2023, Cancer Nanotechnology.
[9] Min Wang,et al. BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer , 2023, Journal for ImmunoTherapy of Cancer.
[10] T. Yamashita,et al. Sclerostin blockade promotes bone metastases of Wnt‐responsive breast cancer cells , 2023, Cancer science.
[11] Baotong Zhang,et al. Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer , 2023, BMC Medicine.
[12] Yue Chen,et al. Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases. , 2023, Molecular pharmaceutics.
[13] H. Wakiyama,et al. Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] Xiaorong Yang,et al. Identification of miR-1-3p, miR-143-3p and miR-145-5p association with bone metastasis of Gleason 3+4 prostate cancer and involvement of LASP1 regulation. , 2023, Molecular and cellular probes.
[15] E. V. Van Allen,et al. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). , 2023, Molecular cancer therapeutics.
[16] Serk In Park,et al. Circulating biomarkers for diagnosis and therapeutic monitoring in bone metastasis , 2023, Journal of Bone and Mineral Metabolism.
[17] E. Denisov,et al. Metastasis prevention: How to catch metastatic seeds. , 2023, Biochimica et biophysica acta. Reviews on cancer.
[18] Lingfeng Zhu,et al. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment , 2023, Experimental Hematology & Oncology.
[19] L. Jian,et al. GPR84 potently inhibits osteoclastogenesis and alleviates osteolysis in bone metastasis of colorectal cancer , 2023, Journal of Orthopaedic Surgery and Research.
[20] Wenlian Chen,et al. Exosomal lncRNA HOTAIR promotes osteoclast differentiation by targeting TGF‐β/PTHrP/RANKL pathway , 2022, Basic & clinical pharmacology & toxicology.
[21] M. Liaghat,et al. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors , 2022, Cell Communication and Signaling.
[22] R. Motzer,et al. Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade , 2022, Nature Reviews Urology.
[23] Y. Lv,et al. Combining dual-targeted liquid metal nanoparticles with autophagy activation and mild photothermal therapy to treat metastatic breast cancer and inhibit bone destruction. , 2022, Acta biomaterialia.
[24] J. Pretell-Mazzini,et al. Management of Long Bones Metastatic Disease: Concepts That We All Know but Not Always Remember , 2022, Orthopedic research and reviews.
[25] Y. Zhang,et al. SPON2 promotes the bone metastasis of lung adenocarcinoma via activation of the NF-κB signaling pathway. , 2022, Bone.
[26] K. Russell,et al. Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial. , 2022, JAMA oncology.
[27] G. Hu,et al. IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer , 2022, The Journal of clinical investigation.
[28] P. Ha,et al. The Role of ECM Remodeling, EMT, and Adhesion Molecules in Cancerous Neural Invasion: Changing Perspectives , 2022, Advanced biology.
[29] Saman Maleki Vareki,et al. Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy , 2022, Cancers.
[30] Katsuhiro Hayashi,et al. The role of surgery in the treatment of metastatic bone tumor , 2022, International Journal of Clinical Oncology.
[31] Hyunsook Kim,et al. RANKL biology. , 2022, Bone.
[32] B. Ruszkowska-Ciastek,et al. Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View , 2022, Biomedicines.
[33] L. Strigari,et al. Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis , 2022, Clinical and Translational Oncology.
[34] M. Barcellos-Hoff,et al. Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment , 2021, Molecular oncology.
[35] A. Grumezescu,et al. Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review , 2021, Cancers.
[36] Libing Song,et al. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling , 2021, Molecular Cancer.
[37] Huile Gao,et al. Self‐Delivered Supramolecular Nanomedicine with Transformable Shape for Ferrocene‐Amplified Photodynamic Therapy of Breast Cancer and Bone Metastases , 2021, Advanced Functional Materials.
[38] Xiaoyu Xu,et al. Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer , 2021, Nature Communications.
[39] Liang Liu,et al. Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts , 2021, Cell Death & Disease.
[40] K. Harada,et al. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study , 2021, International journal of urology : official journal of the Japanese Urological Association.
[41] H. Tseng,et al. The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma , 2021, Cancers.
[42] Bin Bao,et al. The hidden secrets of soluble RANKL in bone biology. , 2021, Cytokine.
[43] P. Sarret,et al. The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers , 2021, Cancer and Metastasis Reviews.
[44] L. Hofbauer,et al. Novel approaches to target the microenvironment of bone metastasis , 2021, Nature Reviews Clinical Oncology.
[45] C. Ieranò,et al. CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment , 2021, Frontiers in Oncology.
[46] S. Achilefu,et al. Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases , 2021, Molecular Cancer Therapeutics.
[47] P. Troncoso,et al. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment , 2021, Clinical Cancer Research.
[48] Lily Yang,et al. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer , 2021, Nature Communications.
[49] A. Gangi,et al. Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study. , 2021, Radiology. Imaging cancer.
[50] L. Qin,et al. Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways , 2021, Molecular Biomedicine.
[51] D. Song,et al. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer , 2021, Clinical Cancer Research.
[52] Yuanming Li,et al. MP46-18 PATIENTS REPORT SATISFACTION/REGRET FOLLOWING FOCAL THERAPY FOR LOCALIZED PROSTATE CANCER: A PROSPECTIVE MULTICENTER EVALUATION , 2021, International Journal of Clinical Oncology.
[53] J. Massagué,et al. Targeting metastatic cancer , 2021, Nature Medicine.
[54] K. Mortezaee,et al. Steps in metastasis: an updated review , 2021, Medical Oncology.
[55] Shukuan Ling,et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells , 2021, Theranostics.
[56] Yayi He,et al. Current progress and mechanisms of bone metastasis in lung cancer: a narrative review , 2021, Translational lung cancer research.
[57] C. Moinpour,et al. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. , 2020, JAMA oncology.
[58] Yi Shi,et al. The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer , 2020, Frontiers in Pharmacology.
[59] E. Danen,et al. Metastasis: crosstalk between tissue mechanics and tumour cell plasticity , 2020, British Journal of Cancer.
[60] Xiaoyu Xu,et al. Bone-targeted oxidative stress nanoamplifier for synergetic chemo/chemodynamic therapy of bone metastases through increasing generation and reducing elimination of ROS , 2020 .
[61] Jonathan M. Morris,et al. Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. , 2020, Journal of vascular and interventional radiology : JVIR.
[62] J. Marchal,et al. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment , 2020, Journal of Hematology & Oncology.
[63] R. M. Pillai,et al. Transitional dynamics of cancer stem cells in invasion and metastasis , 2020, Translational oncology.
[64] C. Klein. Cancer progression and the invisible phase of metastatic colonization , 2020, Nature Reviews Cancer.
[65] B. Durden,et al. Therapy Resistance, Cancer Stem Cells and ECM in Cancer: The Matrix Reloaded , 2020, Cancers.
[66] Jianru Xiao,et al. Targeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges. , 2020, Biomaterials.
[67] Wei Li,et al. Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis , 2020, International Journal of Clinical Pharmacy.
[68] H. Cai,et al. Bone-targeting polymer vesicles for simultaneous imaging and effective malignant bone tumor treatment. , 2020, Biomaterials.
[69] I. Zalaudek,et al. Diagnosis and treatment of melanoma bone metastasis: A multidisciplinary approach , 2020, Dermatologic therapy.
[70] J. Pollard,et al. Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth , 2020, The Journal of experimental medicine.
[71] Yuan Luo,et al. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. , 2020, International journal of biological macromolecules.
[72] C. Mandal. Osteolytic metastasis in breast cancer: effective prevention strategies , 2020, Expert review of anticancer therapy.
[73] Yuquan Wei,et al. Molecular mechanisms and clinical management of cancer bone metastasis , 2020, Bone Research.
[74] Zhen Zhao,et al. Automated diagnosis of bone metastasis based on multi-view bone scans using attention-augmented deep neural networks , 2020, Medical Image Anal..
[75] Shian-Ren Lin,et al. Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis , 2020, Molecules.
[76] N. Mao,et al. A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients. , 2020, European journal of radiology.
[77] V. Goh,et al. Molecular Imaging of Bone Metastases and Their Response to Therapy , 2020, The Journal of Nuclear Medicine.
[78] A. Verma,et al. PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling. , 2020, Biochemical pharmacology.
[79] Y. Wan,et al. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2 , 2020, Nature Communications.
[80] M. Fares,et al. Molecular principles of metastasis: a hallmark of cancer revisited , 2020, Signal Transduction and Targeted Therapy.
[81] S. Dong,et al. Sphingosine‐1‐phosphate (S1P) receptors: Promising drug targets for treating bone‐related diseases , 2020, Journal of cellular and molecular medicine.
[82] G. Yin,et al. Endogenous parathyroid hormone (PTH) signals through osteoblasts via RANKL during fracture healing to affect osteoclasts. , 2020, Biochemical and biophysical research communications.
[83] Hsin-Hung Chen,et al. Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. , 2020, Journal of materials chemistry. B.
[84] Xiangchun Zhang,et al. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis , 2020, Theranostics.
[85] P. Clézardin,et al. The CaSR in Pathogenesis of Breast Cancer: A New Target for Early Stage Bone Metastases , 2020, Frontiers in Oncology.
[86] B. Vincenzi,et al. Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer , 2020, Scientific Reports.
[87] Christopher B. Howard,et al. Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis. , 2020, Biomaterials.
[88] P. Bos,et al. Preoperative embolization in surgical treatment of long bone metastasis: a systematic literature review , 2020, EFORT open reviews.
[89] Weimin Cai,et al. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer , 2020, Theranostics.
[90] E. Tanck,et al. Patient-specific finite element computer models improve fracture risk assessments in cancer patients with femoral bone metastases compared to clinical guidelines. , 2020, Bone.
[91] R. Midura,et al. Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. , 2020, Biomaterials.
[92] Xiaoyu Xu,et al. A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[93] I. Nagtegaal,et al. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival , 2019, Annals of Surgical Oncology.
[94] C. Drake,et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] Yilin Hu,et al. Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells , 2019, Journal of cellular and molecular medicine.
[96] M. Jolly,et al. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition in Cancer Metastasis. , 2019, Cold Spring Harbor perspectives in medicine.
[97] P. Choyke,et al. Near-Infrared Photoimmunotherapy of Cancer , 2019, Accounts of chemical research.
[98] Y. Miyagi,et al. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer , 2019, International journal of cancer.
[99] Jianjun He,et al. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer , 2019, BMC Cancer.
[100] D. Welch,et al. Defining the Hallmarks of Metastasis. , 2019, Cancer research.
[101] S. Rahman,et al. Parathyroid Hormone-Related Protein (PTHrP) Accelerates Soluble RANKL Signals for Downregulation of Osteogenesis of Bone Mesenchymal Stem Cells , 2019, Journal of clinical medicine.
[102] Sakae Tanaka,et al. Early detection of bone metastases of hepatocellular carcinoma reduces bone fracture and paralysis. , 2019, Japanese journal of clinical oncology.
[103] A. Krämer,et al. Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity? , 2019, Front. Oncol..
[104] Min Zhang,et al. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma , 2019, Front. Immunol..
[105] S. Ima-Nirwana,et al. Prostate Cancer and Bone Metastases: The Underlying Mechanisms , 2019, International journal of molecular sciences.
[106] Adrian V. Lee,et al. Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis , 2019, Clinical Cancer Research.
[107] M. Akhtar,et al. Paget’s “Seed and Soil” Theory of Cancer Metastasis: An Idea Whose Time has Come , 2019, Advances in anatomic pathology.
[108] Xinxia Peng,et al. Circulating tumor cells exit circulation while maintaining multicellularity, augmenting metastatic potential , 2019, Journal of Cell Science.
[109] Jacqueline A. Hall,et al. A framework for the development of effective anti-metastatic agents , 2018, Nature Reviews Clinical Oncology.
[110] C. Tulotta,et al. The role of IL-1B in breast cancer bone metastasis , 2018, Endocrine-related cancer.
[111] Yumei Zhang,et al. Bone mesenchymal stem cell secretion of sRANKL/OPG/M-CSF in response to macrophage-mediated inflammatory response influences osteogenesis on nanostructured Ti surfaces. , 2018, Biomaterials.
[112] J. Reagan,et al. Mechanisms of Hypercalcemia in Non‐Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review , 2017, Clinical lymphoma, myeloma & leukemia.
[113] F. Macedo,et al. Bone Metastases: An Overview , 2017, Oncology reviews.
[114] T. Bellido,et al. Role and mechanism of action of sclerostin in bone. , 2017, Bone.
[115] Shun-Fa Yang,et al. Cancer metastasis: Mechanisms of inhibition by melatonin , 2017, Journal of pineal research.
[116] Ping Yang,et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis , 2016, Oncotarget.
[117] A. Mavrogenis,et al. Palliative embolization for metastases of the spine , 2016, European Journal of Orthopaedic Surgery & Traumatology.
[118] T. Dong,et al. Spondin 1 promotes metastatic progression through Fak and Src dependent pathway in human osteosarcoma. , 2015, Biochemical and biophysical research communications.
[119] R. Greil,et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[120] K. Hemminki,et al. Metastatic sites and survival in lung cancer. , 2014, Lung cancer.
[121] N. Girard,et al. Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). , 2014, BoneKEy reports.
[122] F. Farrokhyar,et al. Surgical Management of Bone Metastases: Quality of Evidence and Systematic Review , 2014, Annals of Surgical Oncology.
[123] M. Aapro,et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[124] M. Menon,et al. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. , 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[125] F. Montorsi,et al. Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis , 2014, The Prostate.
[126] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2013, Nature Medicine.
[127] T. Terada,et al. Unusual extrahepatic metastatic sites from hepatocellular carcinoma. , 2013, International journal of clinical and experimental pathology.
[128] J. Jagannathan,et al. Typical and atypical metastatic sites of recurrent endometrial carcinoma , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.
[129] A. Mavrogenis,et al. Embolisation of bone metastases from renal cancer , 2013, La radiologia medica.
[130] C. Gialeli,et al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. , 2012, Biochimica et biophysica acta.
[131] A. Kajdacsy-Balla,et al. The Lymphotactin Receptor Is Expressed in Epithelial Ovarian Carcinoma and Contributes to Cell Migration and Proliferation , 2012, Molecular Cancer Research.
[132] T. Guise,et al. The role of TGF-β in bone metastasis: novel therapeutic perspectives. , 2012, BoneKEy reports.
[133] M. Menon,et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[134] C. O’Brien,et al. Osteocyte RANKL: New insights into the control of bone remodeling , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[135] J. Schneider,et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. , 2012, Cancer research.
[136] G. Steger,et al. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion , 2011, Therapeutic advances in medical oncology.
[137] T. Guise,et al. Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.
[138] D. Lacey,et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[139] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[140] R. Jain,et al. CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? , 2011, Clinical Cancer Research.
[141] T. Mueller,et al. Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways* , 2010, The Journal of Biological Chemistry.
[142] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] P. Mantyh,et al. Bone cancer pain , 2010, Annals of the New York Academy of Sciences.
[144] Yao‐Hua Song,et al. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. , 2009, Cancer letters.
[145] S. French,et al. Metastatic patterns of cancers: results from a large autopsy study. , 2009, Archives of pathology & laboratory medicine.
[146] G. Alexe,et al. Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer? , 2009, Breast Cancer Research and Treatment.
[147] Di Chen,et al. PTHrP prevents chondrocyte premature hypertrophy by inducing cyclin-D1-dependent Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal degradation , 2009, Journal of Cell Science.
[148] J. Pollard,et al. Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.
[149] Yasuhiro Kobayashi,et al. Roles of Wnt signaling in bone formation and resorption , 2008 .
[150] R. Zarnegar,et al. Bone metastases from differentiated thyroid carcinoma. , 2008, Endocrine-related cancer.
[151] G. Clines,et al. Molecular mechanisms and treatment of bone metastasis , 2008, Expert Reviews in Molecular Medicine.
[152] M. Rogers,et al. Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.
[153] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[154] G. Melillo,et al. Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.
[155] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[156] G. Scagliotti,et al. Management of bone metastases in cancer: a review. , 2005, Critical reviews in oncology/hematology.
[157] Antoinette Wetterwald,et al. Molecular and Biological Mechanisms of Bone Metastasis , 2005 .
[158] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[159] K. Pienta,et al. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. , 2005, Neoplasia.
[160] Ora Israel,et al. Positron emission tomography and bone metastases. , 2005, Seminars in nuclear medicine.
[161] G. Oster,et al. The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer , 2005, Oncology.
[162] R. Coleman. Future Directions in the Treatment and Prevention of Bone Metastases , 2002, American journal of clinical oncology.
[163] G. Karsenty,et al. Transcription factors in bone: developmental and pathological aspects. , 2002, Trends in molecular medicine.
[164] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[165] S. Cascinu,et al. Novel therapeutic approaches to cancer patients with bone metastasis. , 2001, Critical reviews in oncology/hematology.
[166] C. Silver,et al. Incidence and Sites of Distant Metastases from Head and Neck Cancer , 2001, ORL.
[167] R. Coleman. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.
[168] R. Coleman,et al. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. , 2001, Seminars in oncology.
[169] T. Yoneda,et al. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. , 2001, Seminars in oncology.
[170] A. Evans,et al. Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. , 2000, Clinical radiology.
[171] G. Andriole,et al. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.
[172] D. Hayes,et al. Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer , 1999, Breast Cancer Research and Treatment.
[173] H. Plotkin,et al. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. , 1998, The Journal of clinical endocrinology and metabolism.
[174] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[175] K. Harrington. Orthopedic surgical management of skeletal complications of malignancy , 1997, Cancer.
[176] D. Rosenthal. Radiologic diagnosis of bone metastases , 1997, Cancer.
[177] A. F. Stewart,et al. Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. , 1997, The Journal of clinical endocrinology and metabolism.
[178] R. Eastell,et al. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. , 1996, Cancer treatment reviews.
[179] R. Wahl,et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.
[180] M. Robson,et al. How is androgen-dependent metastatic prostate cancer best treated? , 1996, Hematology/oncology clinics of North America.
[181] D P Dearnaley,et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[182] R. Rubens,et al. The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.
[183] R. Marcove,et al. The management of pathological fractures. , 1965, The Journal of trauma.
[184] Y. Liao,et al. LncRNA TEX41 regulates autophagy by increasing Runx2 expression in lung adenocarcinoma bone metastasis. , 2023, American journal of translational research.
[185] R. Kremer,et al. Parathyroid Hormone-Related Protein (PTHrP): An Emerging Target in Cancer Progression and Metastasis. , 2019, Advances in experimental medicine and biology.
[186] 竹井 祥郎,et al. Handbook of hormones : comparative endocrinology for basic and clinical research , 2016 .
[187] H. Lepor,et al. LHRH Agonists for the Treatment of Prostate Cancer: 2012. , 2012, Reviews in urology.
[188] R. Kalluri,et al. Contribution of bone microenvironment to leukemogenesis and leukemia progression , 2009, Leukemia.
[189] K. Pienta,et al. Expression and activation of αvβ3 integrins by SDF‐1/CXC12 increases the aggressiveness of prostate cancer cells , 2007 .
[190] Xiyun Deng,et al. CXCL12/CXCR4 signaling activates Akt‐1 and MMP‐9 expression in prostate cancer cells: The role of bone microenvironment‐associated CXCL12 , 2006, The Prostate.
[191] K. Pienta,et al. Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone , 2004, Cancer and Metastasis Reviews.
[192] I. Macdonald,et al. Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.
[193] C. Denkert,et al. Expression of cyclooxygenase 2 in human malignant melanoma. , 2001, Cancer research.
[194] R. Rubens,et al. Clinical course and prognostic factors following bone recurrence from breast cancer. , 1998, British Journal of Cancer.
[195] A. F. Stewart,et al. Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. , 1996, The Journal of clinical endocrinology and metabolism.
[196] M. Gillespie,et al. Parathyroid Hormone-Related Protein , 1995 .